Andrew  Komjathy net worth and biography

Andrew Komjathy Biography and Net Worth

Andrew Komjathy serves as Chief Commercial Officer of the Company. Mr. Komjathy was the Vice President, Commercial Sales at Alkermes, Inc., a publicly held pharmaceutical company, from May 2014 to November 2018. From 2012 to 2014, he was the Vice President, Sales for the U.S. Multiple Sclerosis Business Unit at Genzyme, a publicly held pharmaceutical company. From 2005 to 2012, Mr. Komjathy held three Vice President positions at Shire Human Genetic Therapies, initially as Vice President and General Manager, Commercial Operations in the North American and Asia-Pacific regions, followed by Vice President, Global Franchise Leader for Fabry/Gaucher in Switzerland, and ultimately as Vice President, Commercial Operations. From 1996 to 2005, Mr. Komjathy held positions of increasing responsibility at Biogen. Mr. Komjathy holds an M.B.A. from New York University Stern School of Business and his B.S. in Business Administration from Bucknell University.

How do I contact Andrew Komjathy?

The corporate mailing address for Mr. Komjathy and other Astria Therapeutics executives is 100 High StreetFloor 28, Boston MA, 02110. Astria Therapeutics can also be reached via phone at (617) 349-1971 and via email at [email protected]. Learn More on Andrew Komjathy's contact information.

Has Andrew Komjathy been buying or selling shares of Astria Therapeutics?

Andrew Komjathy has not been actively trading shares of Astria Therapeutics in the last ninety days. Most recently, on Friday, November 19th, Andrew Komjathy bought 100 shares of Astria Therapeutics stock. The stock was acquired at an average cost of $6.70 per share, with a total value of $670.00. Learn More on Andrew Komjathy's trading history.

Who are Astria Therapeutics' active insiders?

Astria Therapeutics' insider roster includes Andrew Komjathy (Insider), and Christopher Morabito (insider). Learn More on Astria Therapeutics' active insiders.

Andrew Komjathy Insider Trading History at Astria Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Buy100$6.70$670.00View SEC Filing Icon  
See Full Table

Andrew Komjathy Buying and Selling Activity at Astria Therapeutics

This chart shows Andrew Komjathy's buying and selling at Astria Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Astria Therapeutics Company Overview

Astria Therapeutics logo
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $13.12
Low: $13.06
High: $13.29

50 Day Range

MA: $11.33
Low: $7.28
High: $13.12

2 Week Range

Now: $13.12
Low: $3.56
High: $13.29

Volume

2,775,318 shs

Average Volume

1,129,521 shs

Market Capitalization

$748.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07